FOODS ENHANCED WITH PROVEN HEALTH BENEFITS NOT MAKING IT TO CONSUMERS QUICKLY ENOUGH
Tools for tackling global epidemics of malnutrition, obesity and their associated health problems are stuck in ‘development limbo’, says GM expert
Professor Johnathan Napier, who pioneered the development of plants that produce heart healthy omega-3 fish oils, says that misinformation and over-regulation is stopping or slowing several GM foods with the potential to save lives from making it to consumers.
He points to the example of Golden Rice, which has been genetically modified to provide more Vitamin A than other rice varieties and was first created by scientists nearly 20 years ago, with the initial concept developed at least 10 years before that.
Professor Napier said: “Vitamin A deficiency is a huge problem in the developing world, killing or blinding over a million children a year and effecting hundreds of millions of people in total. Yet, as of last year, no golden rice has ever been grown for human consumption.
“The technology is proven, the rigorous safety studies have been done, the nutritional research shows Golden Rice is an excellent source of vitamin A – but still it is not being produced, despite having been formally approved for feed or food use in USA, Canada and New Zealand and Australia.
“It’s been stuck in development limbo for far too long now, and not available to the people who would benefit from it. If there was a pharmaceutical that could achieve a similar public health benefit but wasn’t being made available, there would be a public outcry over it. And unlike many drugs, Golden Rice has been made not-for-profit by its creators.”
Whilst many enhanced crops traits are aimed at tackling malnutrition in developing countries, others target the health impacts of obesity - such as heart disease, diabetes and strokes - that currently blight most developed countries.
Writing in the journal Nature Plants, Professor Napier and colleagues argue, based on lessons learned by the whole sector over many years, that there are four main areas where issues may arise and impede the delivery of crops with nutritional enhancements to consumers: the economic value-chain, the patent system, the regulatory system and societal acceptance.
And whilst these areas per se don’t all directly impact on speed of delivery, how each is dealt with will certainly affect progress, he says.
“We are keen to avoid these pitfalls and want to highlight them to others too, especially with the new wave of potential crops with nutritional enhancements.”
These enhancements include tomatoes high in anthocyanins, Professor Napier’s own omega-3 study system, and various cereals fortified with iron or extra vitamins, such as folic acid.
The authors say that in many cases, these barriers are stopping such improved crops even making it out of the lab.
“What we need is a different innovation pathway, one that isn’t reliant on market forces and economics, to speed up this process,” says Professor Napier. “When you consider much of the science behind these developments has been publicly funded to the tune of hundreds of millions of pounds, at the very least we owe it to the taxpayer to deliver the promised benefits.”
Rather than rely on industry to invest in and develop these scientific breakthroughs, the authors suggest that this public funding is continued to help navigate the regulation process and produce an end-product for the consumer.
Professor Napier said: “One can easily imagine a model whereby the costs of this would be offset by the savings to national health services from having healthier populations. Not only that, the public essentially become stakeholders in the product, which might help allay much of the suspicion around the motives of multinationals that accompany many new products within both agriculture and medicine.”
Co-author Dr Matina Tsalavouta, Head of Research and Impact Marketing and Communications at the University of Liverpool, said there is an opportunity to create an effective pathway to delivering solutions as fast as it is practically possible to those who need it most.
“The issues outlined in the paper also suggest that it is critical to work across disciplines and expertise, bringing together economists, public health researchers, intellectual property experts, social scientists and end users, to explore all the issues that may arise from the use of the remarkable technological advances in the life sciences. This approach has the potential to enable more effective development of solutions to pressing global health challenges,” she added.
About Rothamsted Research
Rothamsted Research is the longest-running agricultural research institute in the world. We work from gene to field with a proud history of ground-breaking discoveries, from crop treatment to crop protection, from statistical interpretation to soils management. Our founders, in 1843, were the pioneers of modern agriculture, and we are known for our imaginative science and our collaborative influence on fresh thinking and farming practices.
Through independent science and innovation, we make significant contributions to improving agri-food systems in the UK and internationally. In terms of the institute’s economic contribution, the cumulative impact of our work in the UK was calculated to exceed £3000 million a year in 20151. Our strength lies in our systems approach, which combines science and strategic research, interdisciplinary teams and partnerships.
Rothamsted is also home to three unique resources. These National Capabilities are open to researchers from all over the world: The Long-Term Experiments, Rothamsted Insect Survey and the North Wyke Farm Platform.
We are strategically funded by the Biotechnology and Biological Sciences Research Council (BBSRC), with additional support from other national and international funding streams, and from industry. We are also supported by the Lawes Agricultural Trust (LAT).
For more information, visit https://www.rothamsted.ac.uk/; Twitter @Rothamsted
1Rothamsted Research and the Value of Excellence: A synthesis of the available evidence, by Séan Rickard (Oct 2015)
The Biotechnology and Biological Sciences Research Council is part of UK Research and Innovation, a non-departmental public body funded by a grant-in-aid from the UK government.
BBSRC invests in world-class bioscience research and training on behalf of the UK public. Our aim is to further scientific knowledge, to promote economic growth, wealth and job creation and to improve quality of life in the UK and beyond.
Funded by government, BBSRC invested £469 million in world-class bioscience in 2016-17. We support research and training in universities and strategically funded institutes. BBSRC research and the people we fund are helping society to meet major challenges, including food security, green energy and healthier, longer lives. Our investments underpin important UK economic sectors, such as farming, food, industrial biotechnology and pharmaceuticals.
More information about BBSRC, our science and our impact.
More information about BBSRC strategically funded institutes
The Lawes Agricultural Trust, established in 1889 by Sir John Bennet Lawes, supports Rothamsted Research’s national and international agricultural science through the provision of land, facilities and funding. LAT, a charitable trust, owns the estates at Harpenden and Broom's Barn, including many of the buildings used by Rothamsted Research. LAT provides an annual research grant to the Director, accommodation for nearly 200 people, and support for fellowships for young scientists from developing countries. LAT also makes capital grants to help modernise facilities at Rothamsted, or invests in new buildings.